Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.
The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.
Tarrytown, New York Wednesday, March 4, 2026, 13:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results